0.88p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genedrive
Its shares trade on LSE under the ticker GDR.L. It has been listed since 4 April 2007. In the fiscal year to 30 June 2025, it reported revenue of £764,000 and a net loss of £5.2m. At that date it held total assets of £2.8m and shareholders' equity of £1.4m.
Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The firm provides a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Its geographical segments include the United Kingdom, Europe, the United States of America and Asia. Genedrive is a small polymerase chain reaction (PCR) platform, which enables nucleic acid amplification and detection from various sample types, including plasma, sputum and buccal swabs. Genedrive system includes Genedrive hepatitis C virus (HCV) ID Kit for detection of Hepatitis C, and Genedrive IL28B ID Kit for the detection of Interleukin 28B genotyping status.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 4 Apr 2007
- Employees
- 46
- Website
- genedriveplc.com ↗
Leadership
Pay as last reported
- Dr. Ian GilhamNon-Executive Chairman of the Board, since 2014£65,000
- Dr. Gino MieleChief Executive Officer, Chief Scientific Officer, Executive Director, since 2023£173,202
- Mr. Russell ShawChief Financial Officer, Executive Director, Company Secretary, since 2022£214,911
- Mr. Tom LindsayNon-Executive Director£35,000
- Mr. Christopher YatesNon-Executive Director£35,000
- Mr. Paul McmanusFinancial PR and Investor Relations, since 2019
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genedrive PLC is a leading provider of molecular diagnostics solutions, possessing cutting-edge technology and expertise in the field.
- The company has a diverse product portfolio, offering a range of diagnostic tests that are highly accurate, rapid, and easy to use.
- Genedrive PLC has established strong partnerships and collaborations with renowned healthcare organizations, enhancing its market reach and credibility.
Weaknesses
- Genedrive PLC heavily relies on its key products for revenue generation, which exposes the company to potential financial risks if these products face market challenges or fail to meet customer expectations.
- The company's limited geographical presence and customer base in certain regions may hinder its growth potential.
Opportunities
- The increasing demand for rapid and accurate molecular diagnostic tests presents a significant growth opportunity for Genedrive PLC.
- Advancements in technology and increasing investments in healthcare infrastructure globally offer the company opportunities to expand its product offerings and enter new markets.
- Genedrive PLC can leverage its expertise to develop diagnostic solutions for emerging diseases and public health emergencies, such as the COVID-19 pandemic, opening doors to collaborations with governments and international organizations.
Threats
- Intense competition within the molecular diagnostics industry poses a threat to Genedrive PLC's market share and profitability.
- Changes in regulatory policies and stringent approval processes for diagnostic tests can impact the company's ability to launch new products and achieve timely market access.
- Global economic uncertainties and budget constraints in healthcare expenditure may limit Genedrive PLC's potential for revenue growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.